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Mitochondria are of central importance for energy generation in skeletal muscles. Expression changes or functional alterations in
mitochondrial enzymes play a key role during myogenesis, fibre maturation, and various neuromuscular pathologies, as well as
natural fibre aging. Mass spectrometry-based proteomics suggests itself as a convenient large-scale and high-throughput approach
to catalogue the mitochondrial protein complement and determine global changes during health and disease. This paper gives a
brief overview of the relatively new field of mitochondrial proteomics and discusses the findings from recent proteomic surveys of
mitochondrial elements in aged skeletal muscles. Changes in the abundance, biochemical activity, subcellular localization, and/or
posttranslational modifications in key mitochondrial enzymes might be useful as novel biomarkers of aging. In the long term, this
may advance diagnostic procedures, improve the monitoring of disease progression, help in the testing of side effects due to new
drug regimes, and enhance our molecular understanding of age-related muscle degeneration.
1. Introduction
The neuromuscular system is severely affected during the
natural aging process [1]. Pathophysiological cycles of dener-
vation and impaired reinnervation, the loss of entire motor
units, unloading due to prolonged periods of disuse, and
excitation-contraction uncoupling may trigger a substantial
loss in skeletal muscle mass and function [2]. Although con-
siderable interindividual differences exist in the functional
decline of the musculature during aging, most elderly people
experience a general loss in skeletal muscle strength [3].
While regular physical activity and a protein-rich diet can
partially counteract severe muscle wasting [4], a sedentary
life style and certain medical conditions, such as diabetes,
cancer, renal failure, chronic obstructive pulmonary disease,
or congestive heart failure [5–7], clearly promote muscle
degeneration [8]. Skeletal muscle wasting plays a crucial role
in physical disability, frailty, and loss of independence in
aged people [9]. Skeletal muscle wasting in the elderly has
been termed sarcopenia of old age, whereby this muscular
impairment is probably due to multiple factors [10], as out-
lined in Figure 1. On the cellular level, a variety of abnormal
structural, physiological, and biochemical processes have
been identified that are directly or indirectly associated with
age-dependent muscle wasting. This includes a severe decline
in contractile efficiency [11], increased apoptosis [12],
denervation-associated atrophy [13], bioenergetic changes
[14], impaired ion homeostasis [15], excitation-contraction
uncoupling [16], decreased capacity for fibre regeneration
[17], a partially diminished cellular stress response [18],
and an altered equilibrium of hormones and growth factors
crucial for the maintenance of contractile function [19],
as well as oxidative stress and mitochondrial abnormalities
[20–22]. The general issue of fibre type shifting during
aging is still controversial. Although individual muscles
in aged humans and animal models of sarcopenia exhibit
alterations in the molecular composition of contractile fibres
and changes in their glycolytic and aerobic capacity, findings
on distinct shifts in fibre types with aging are highly variable
[23–26]. However, since mitochondrial functions are clearly
impaired in senescent muscle tissues, it was of interest to
summarize the impact of recent mass spectrometry-based
proteomic studies on the molecular fate of mitochondrial
enzymes in senescent fibres. This paper briefly outlines
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Figure 1: Overview of the multifactorial etiology of sarcopenia.
Shown are the main physiological and biochemical events that
trigger chronic tissue wasting and severe contractile weakness in
senescent skeletal muscles. One of the most striking age-related
changes is a drastic alteration in the abundance of mitochondrial
enzymes.
the proposed role of mitochondria in cellular senescence
and recent achievements of mitochondrial proteomics and
then focuses on findings from proteomic profiling studies of
aged skeletal muscle preparations and the identification of
mitochondrial elements as potential markers of fibre aging.
2. Mitochondria and Cellular Senescence
Mitochondria are the primary site for energy generation via
oxidative phosphorylation and play a key role in protein
transport, intermediary metabolism, cell cycle progression,
calcium signaling, and the regulation of apoptosis [27].
Proteomic cataloguing studies of this crucial organelle
suggest the existence of approximately 1,500 mitochondrial
proteins [28–30], whereby altered expression levels within
the mitochondrial proteome are critical factors for normal
development and numerous diseases [31–33]. Changes in
mitochondria have long been associated with playing an
integral role during natural aging [34–37], and the phar-
macological application of antioxidants for counteracting
mitochondria-specific symptoms of senescence is being
extensively studied [38]. Interestingly, the mitochondrial
theory of aging also encompasses the mechanisms that may
lead to cellular senescence in contractile tissues [39–41].
Altered levels ofmitochondrial activity in agedmuscle tissues
have been well established and extensively reviewed [42–
44]. The detrimental accumulation of mitochondrial DNA
deletions and mutations on the genetic level and deficien-
cies in the mitochondrial electron transport chain on the
biochemical level are clearly associated with muscle aging.
The pathological consequences of an age-related decline in
mitochondrial function are the impairment of essential ATP-
dependent cellular processes [45] and amplified oxidative
stress in senescent tissues due to the increased release of
reactive oxygen species from the mitochondrial respira-
tory chain [46, 47]. In general, senescent muscle tissues
are exposed to an enhanced production of mitochondrial
reactive oxygen species, increased mitochondrial apoptotic
susceptibility, disturbed mitochondrial bioenergetic func-
tions, and a reduced transcriptional drive for mitochondrial
biogenesis [22, 48]. Although these functional impairments
clearly occur in skeletal muscle mitochondria during aging,
biochemical studies have also demonstrated considerable
age-related changes in the abundance and posttranslational
modifications of key mitochondrial enzymes.
3. Profiling of the Mitochondrial Proteome
Proteomics is concerned with the large-scale and high-
throughput identification and characterization of the global
protein constellation of a given biological entity, such as
cells, tissues, or body fluids [49]. Protein complements are
separated by standard methods, including gel electrophoresis
and liquid chromatography [50–52], and individual pro-
tein species are usually identified by mass spectrometry
[53–55]. The verification of proteomic data is routinely
carried out by biochemical, immunological, cell biological,
and physiological assays. Skeletal muscle proteomics, in
particular, involves the comprehensive biochemical anal-
ysis of protein populations from defined muscle tissues,
individual muscles, specific fibre populations, or distinct
subcellular fractions [56–58]. Figure 2 outlines the standard
workflow for the identification of novel aging-associated
biomarkers using gel electrophoresis-based proteomics. Total
crude tissue extracts, detergent phase-extracted proteins,
or mitochondria-enriched fractions are routinely used as
starting material for the determination of newmitochondrial
markers. The main analytical steps involved in skeletal
muscle proteomics are the extraction of a distinct protein
population from crude extracts, subcellular fractions, or
affinity-purified protein complexes, the efficient separation
of proteins by one-dimensional gel electrophoresis, two-
dimensional gel electrophoresis, or liquid chromatography,
the densitometric mapping of altered protein concentration
levels, the unequivocal identification of protein species by
mass spectrometry of protease-generated peptide mixtures,
and finally the independent validation of proteomic data by
enzyme assays, immunoblot analysis, ligand binding assays,
or immunofluorescence microscopy.
Since the concentration range of proteins is not a static
entity, but highly dynamic, and because the density of
proteins spans several orders of magnitude in complex
cellular systems, proteomic studies of crude extracts result
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mostly in the cataloguing of abundant and soluble protein
species. Thus, conventional gel electrophoresis-based pro-
teomics underestimates certain classes of proteins, such as
high-molecular-mass proteins, integral membrane proteins,
extremely basic or acid proteins, and low-abundance pro-
teins [50–52]. Over the last few years, proteomic approaches
have been refined in order to reduce sample complexity by
subcellular fractionation protocols and affinity separation
techniques [59–61]. Mass spectrometry-based proteomics
suggests itself as an ideal analytical method to determine
global changes in the mitochondrial protein complement
[62, 63]. Mitochondrial proteomics is concerned with the
establishment of the entire organelle-associated protein
complement and the dynamic nature of posttranslational
modifications in mitochondrial components, as well as
differential expression patterns within mitochondrial protein
populations due to physiological adaptations or pathological
insults [64–66]. Considerable tissue-specific differences exist
within the mitochondrial proteome and reflect the diversity
of mitochondrial functions in individual organs [67–69]. As
listed in Table 1, proteomic maps of mitochondria exist for
numerous organs from several different species.
The first comprehensive survey of human mitochon-
dria detected approximately 1,500 spots on a silver-stained
reference map and identified 46 mitochondria-associated
proteins in placental tissue [70]. Subsequent studies have
discovered several hundred mitochondrial proteins by mass
spectrometry, using differential centrifugation or density
gradients consisting of percoll, metrizamide or nycodenz
for prefractionation purposes [71–77]. Proteomic analyses
yielded 615, 680 and 940 distinct mitochondrial proteins in
human and mouse heart, respectively [71–73], 182 and 192
mitochondrial proteins in mouse and rat liver, respectively
[74, 75], 823 mitochondrial proteins in human skeletal
muscle [76], and 723 and 1,198 mitochondrial proteins in
brown and white fat cell lines, respectively [77]. Several
proteomic studies have investigated mitochondrial protein
populations in several organ systems in parallel, including
liver, muscle, heart, kidney, and brain [67–69]. The most
comprehensive comparative report on the mitochondrial
proteome has created a compendium of 1,098 genes and their
protein expression across 14 mouse tissues [78]. Detailed
listings of proteomic studies that have focused on mitochon-
dria in health and disease can be found in recent extensive
reviews of this specialized field of subproteomics [28, 30, 65].
These crucial cataloguing exercises form now the basis of
detailed comparative investigations into disease-dependent
alterations in mitochondria [64], including studying the
effects of aging on the mitochondrial proteome [79, 80].
4. Mitochondrial Markers of
Skeletal Muscle Aging
Over the last decade, a large number of proteomic stud-
ies have identified potential biomarkers of muscle aging
[81]. Studies of aged human muscle and the most widely
employed animal model of sarcopenia-related abnormalities,
the senescent rat [82], have revealed changes in proteins
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Figure 2: Flowchart of the proteomic workflow to identify and
characterize novel mitochondrial markers involved in sarcopenia
of old age. Shown are the various steps involved in the high-
throughput proteomic screening of tissue specimens, including
sample preparation, gel electrophoretic separation, densitometric
analysis, and mass spectrometric identification of new candidate
proteins.
involved in the regulation of excitation-contraction cou-
pling, ion homeostasis, muscle contraction, muscle relax-
ation, metabolite transportation, energy metabolism, and
the cellular stress response [83–99]. Table 2 lists recent pro-
teomic studies that have identified the potential involvement
of mitochondrial elements in sarcopenia of old age. The
proteomic analysis of total extracts from aged human vastus
lateralis muscle has identified numerous aerobic markers
with an increased density, including the mitochondrial
enzymes ATP synthase, ubiquinol-cytochrome c reductase,
and oxoglutarate dehydrogenase during muscle aging [86].
In analogy, elevated levels of mitochondrial enzymes, such
as succinate dehydrogenase, isocitrate dehydrogenase, ATP
synthase, malate dehydrogenase, ubiquinol-cytochrome c
reductase, and pyruvate dehydrogenase, were also shown
to occur during the aging of rat gastrocnemius muscle
[93, 94]. These investigations were performed with the
fluorescence difference in-gel electrophoretic technique, one
of the most powerful biochemical methods to compare
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Table 1: List of major profiling studies of the mitochondrial proteome.
Proteomic studies Mitochondrial protein identification Reference
Proteomic analysis of
human placenta
First comprehensive cataloguing of the mitochondrial proteome, which
resulted in the identification of 46 distinct proteins
Rabilloud et al. [70]
Analysis of human and
mouse heart
Identification of 680 human mitochondrial proteins and 940 mouse
mitochondrial proteins in heart muscle
Taylor et al. [71],
Gaucher et al. [72],
Zhang et al. [73]
Proteomic profiling of
mouse and rat liver
Identification of 182 mouse proteins and 192 rat proteins that are associated
with liver mitochondria
da Cruz et al. [74],
Fountoulakis et al. [75]
Proteomic profiling of
human skeletal muscle
Identification of 823 mitochondrial proteins in human vastus lateralis
muscle
Lefort et al. [76]
Proteomic profiling of
brown and white adipose
cell lines
Identification of 723 mitochondrial proteins in brown adipose cell line and
1,198 mitochondrial proteins in white adipose cell line
Forner et al. [77]
Comparative studies for the
establishment of the
mammalianmitochondrial
proteome from various
tissues
Identification of tissue-specific expression patterns of mouse and rat
mitochondrial proteins from liver, skeletal muscle, kidney, brain, heart, and
various other organs. The most comprehensive comparative study
established the mitochondrial protein complement in 14 different tissues
Mootha et al. [67],
Forner et al. [68],
Reifschneider et al. [69],
Pagliarini et al. [78]
concentration changes of distinct protein species in sol-
uble proteomes [100]. The recent proteomic profiling of
the detergent phase-extracted protein complement from
senescent rat gastrocnemius muscle confirmed a changed
concentration of numerous mitochondrial enzymes during
aging. The mitochondrial marker enzymes ATP synthase
and isocitrate dehydrogenase were found to be significantly
increased in agedmuscle tissue [99]. In contrast to the highly
discriminatory difference in-gel electrophoretic technique
used for studying muscle aging [86, 93, 94, 97], proteomic
approaches with conventional protein dyes or dyes that cover
a limited dynamic range have identified considerably fewer
changes in mitochondrial markers [85, 87].
Subproteomic studies of mitochondria-enriched frac-
tions from aged skeletal muscles have shown differential
effects on the abundance of mitochondrial enzymes [90,
91, 96–98]. Chang et al. [90] have studied the effect of
aging and caloric restriction on the rat mitochondrial
proteome. In skeletal muscles, isocitrate dehydrogenase and
malate dehydrogenase were shown to be increased in 25-
month-old Fisher 344 rats, as compared to 6-month-old
rats. Caloric restriction appears to have only a minor
effect on age-related changes in the mitochondrial protein
complement [90]. Severe metabolic changes in aged skeletal
muscle were confirmed by an extensive proteomic survey
of mitochondrial preparations from 3-month-old versus 26-
month-old rat gastrocnemius muscles [97]. These muscle
specimens represent young adult versus senescent contractile
tissues, respectively. The fluorescent difference in-gel elec-
trophoretic analysis demonstrated an age-dependent eleva-
tion in numerous mitochondrial proteins, including NADH
dehydrogenase, ATPase synthase, succinate dehydrogenase,
the mitochondrial inner membrane protein mitofilin, per-
oxiredoxin isoform PRX-III, mitochondrial fission protein
Fis1, succinate-coenzyme A ligase, acyl-coenzyme A dehy-
drogenase, ubiquinol-cytochrome c reductase core I protein,
prohibitin, and porin isoform VDAC2 (Figure 3).
Proteomic studies of posttranslational changes in aged
skeletal muscle have revealed increased nitration levels in
succinate dehydrogenase [83], decreased phosphorylation
levels in cytochrome c oxidase and aconitase [92], and altered
carbonylation levels in ATP synthase, NADHdehydrogenase,
pyruvate dehydrogenase, and isocitrate dehydrogenase [91]
during muscle aging [101]. Abnormal posttranslational
modifications may alter protein stability, subcellular tar-
geting, intra- and intermolecular interactions, as well as
coupling efficiency between substrates and active sites in
affected mitochondrial enzymes. This might partially explain
impaired mitochondrial functioning in senescent fibres.
Thus, natural aging of skeletal muscles appears to be associ-
ated with distinct changes in posttranslational modifications
of important mitochondrial enzymes. Recently, Ferreira et al.
[102] compared the proteomes of subsarcolemmal versus
intermyofibrillar mitochondria from rat skeletal muscle.
A differential expression pattern was established for 38
mitochondrial proteins. In the future, refined proteomic
studies might be able to determine whether intermyofibrillar
mitochondria are differently affected by muscle aging as
compared to subsarcolemmal mitochondria.
5. Conclusion
Since improved nutritional intake and exercise intervention
can only partially alleviate the symptoms of sarcopenia, there
is an urgent need to develop novel pharmacological strate-
gies to prevent age-related muscle wasting [103]. Recent
publications by working groups on the etiology, epidemiol-
ogy, potential interventions, and the clinical assessment of
sarcopenia show that a general definition of this common
geriatric syndrome is still evolving [104–109]. In the future,
it will be crucial to establish reliable sarcopenia-specific
biomarkers to develop superior diagnostic tools for the
correct classification of this age-dependent muscle pathology
[110]. Mass spectrometry-based proteomics suggests itself
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Table 2: Proteomic identification of mitochondrial proteins during skeletal muscle aging.
Proteomic study Changes in mitochondrial marker proteins Reference
Analysis of total extracts
from aged human vastus
lateralis muscle
General increase in aerobic markers, including mitochondrial enzymes such
as ATP synthase, ubiquinol-cytochrome c reductase, and oxoglutarate
dehydrogenase during muscle aging
Gelfi et al. [86]
Analysis of total extracts
from rat gastrocnemius
muscle
Increase in mitochondrial enzymes, such as succinate dehydrogenase,
isocitrate dehydrogenase, ATP synthase, and malate dehydrogenase during
muscle aging
Doran et al. [93]
Analysis of total extracts
from rat gastrocnemius
muscle
Differential effect on the abundance of mitochondrial isoforms of aconitase
during muscle aging
O’Connell et al. [87]
Analysis of total extracts
from aged rat
gastrocnemius muscle
Moderate effect on cytochrome c oxidase and isocitrate dehydrogenase
during muscle aging
Piec et al. [85]
Analysis of total extracts
from rat gastrocnemius
muscle
Increase in many enzymes involved in oxidative metabolism, such as ATP
synthase, isocitrate dehydrogenase, ubiquinol-cytochrome c reductase, and
pyruvate dehydrogenase during muscle aging
Capitanio et al. [94]
Subproteomic study of the
effect of aging and caloric
restriction on rat muscle
mitochondria
Increased levels of isocitrate dehydrogenase and malate dehydrogenase in
aged muscle mitochondria. Caloric restriction appears to have only a
marginal effect on the mitochondrial proteome
Chang et al. [90]
Subproteomic analysis of
mitochondria-enriched
fraction from aged rat
gastrocnemius muscle
Increased levels of mitochondrial creatine kinase, NADH dehydrogenase,
ATP synthase, succinate dehydrogenase, and ubiquinol cytochrome c
reductase during muscle aging
O’Connell and
Ohlendieck [97]
Analysis of total extracts
and mitochondria-enriched
fraction from aged
ratgastrocnemius muscle
Differential effect on mitochondrial enzymes, such as pyruvate
dehyrdogenase, cytochrome c oxidase, isocitrate dehydrogenase, and ATP
synthase during muscle aging
Lombardi et al. [96]
Subproteomic analysis of
mitochondria-enriched
fraction from aged mouse
hind limb muscles
Differential effects on the abundance and carbonylation of various
mitochondrial enzymes, including NADH dehydrogenase, cytochrome c
oxidase, and ATP synthase during muscle aging
Alves et al. [98]
Analysis of detergent
phase-extracted protein
complement from aged rat
gastrocnemius muscle
Increase in mitochondrial marker enzymes, such as ATP synthase and
isocitrate dehydrogenase during muscle aging
Donoghue et al. [99]
Proteomic analysis of
nitration in aged rat
skeletal muscle
Increased nitration levels in succinate dehydrogenase Kanski et al. [84]
Phosphoproteomic analysis
of total extracts from aged
rat gastrocnemius muscle
Decreased phosphorylation levels in cytochrome c oxidase and aconitase
during muscle aging
Gannon et al. [92]
Proteomic analysis of
carbonylation in aged rat
skeletal muscle
mitochondria
Altered carbonylation levels in numerous mitochondrial proteins, including
ATP synthase, NADH dehydrogenase, pyruvate dehydrogenase, and
isocitrate dehydrogenase during muscle aging
Feng et al. [91]
as an ideal analytical tool for the study of skeletal muscle
aging. The biochemical establishment of a robust protein
marker signature for sarcopenia of old age will be extremely
useful for (i) formulating a coherent cellular theory of
muscle aging, (ii) the development of proper diagnostic
criteria that can differentiate between different degrees
of age-related muscle weakness, (iii) the identification of
novel therapeutic targets to counteract cellular stress and
fibre degeneration during aging, and (iv) the evaluation of
improved treatment regimes to slow down the aging process.
Recent proteomic studies of mitochondria-enriched frac-
tions and total skeletal muscle extracts have demonstrated
altered levels of key mitochondrial enzymes in senescent
muscle tissues. Aged neuromuscular systems appear to
contain a higher degree of certain mitochondrial enzymes.
Thus, although mitochondrial dysfunction and oxidative
stress are associated with sarcopenia, muscle aging is also
clearly linked to metabolic alterations. This suggests that
abundant mitochondrial enzymes may be useful for general
muscle profiling and are excellent biomarker candidates for
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Figure 3: Proteomic profiling of the mitochondria-enriched fraction from aged skeletal muscle tissue. Shown is the comparative graphic
representation of distinct two-dimensional protein spots with a changed expression in aged muscle as judged by fluorescence difference
in-gel electrophoretic analysis [97]. Individual panels document alterations in the abundance of NADH dehydrogenase (NADH-DH), the
inner mitochondrial membrane protein mitofilin, prohibitin, the porin isoform VDAC 2, succinate dehydrogenase (SDH), acyl-coenzyme
A dehydrogenase (Acyl-CoA-DH), peroxiredoxin isoform PRX-III, ubiquinol-cytochrome c reductase core I protein (Ubq-Cytc-RED),
succinate-coenzyme A (Suc-CoA) ligase, and mitochondrial F1-ATPase.
the biochemical classification of cellular changes during the
natural aging process.
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